Amodiaquine pharmacogenetics

Pharmacogenomics

Volumn 9, Issue 10, 2008, Pages 1385-1390

  Gil, Jose Pedro ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTESUNATE; BENFLUMETOL; COARSUCAM; CYTOCHROME P450 2C8; DEETHYLAMODIAQUINE; MEFLOQUINE; PACLITAXEL; UNCLASSIFIED DRUG; WINTHROP;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENDEMIC DISEASE; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; HALF LIFE TIME; HUMAN; LIVER INJURY; LIVER TOXICITY; MALARIA; MALARIA CONTROL; MONOTHERAPY; NEUTROPENIA; PHARMACOGENETICS; PHENOTYPE; PLASMODIUM FALCIPARUM;

ALLELES; AMODIAQUINE; ANIMALS; ANTIMALARIALS; CYTOCHROME P-450 ENZYME SYSTEM; ENDEMIC DISEASES; FORECASTING; HALF-LIFE; HUMANS; MALARIA, FALCIPARUM; MODELS, BIOLOGICAL; PHARMACOGENETICS; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC;

EID: 55449092377     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.10.1385     Document Type: Article

References (45)

1. Sachs JD, Hotez PJ: Fighting tropical diseases. Science 311(5767), 1521 (2006).
2. Nosten F, White NJ: Artemisinin-based combination treatment of falciparum malaria. Am. J Trop. Med. Hyg. 77(Suppl. 6), 181-192 (2007).
3. Burckhalter JH, Tendwick JH, Jones FH, Jones PA, Holcome HE Rawlins AL: Aminoalkilphenols as antimalarials II (heterocyclo-amino)-amino-o-cresols: the synthesis of camoquine. J Am. Chem. Soc. 70, 1363-1373 (1948)
4. Olliaro F, Mussano P: Amodiaquine for treating malaria. Cochrane Database Syst. Rev. 2, CD000016. DOI: 10.1002/14651858 (2003) (Epub ahead of print).
5. Hatton CS, Peto TE, Bunch C et al.: Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1 (8478), 411-414 (1986).
6. Neftel KA, Wooddy W, Schmid M, Frick PG, Fehr J: Amodiaquine induced agranulocytosis and liver damage. Br. Med. J. 292(6522), 721-723 (1986).
7. Larrey D, Castot A, Pëssayre D et al.:0 Amodiaquine-induced hepatitis. A report of seven cases. Ann. Intern. Med. 104(6), 801-803 (1986).
8. Rouveix B, Coulombel L, Aymard JP, Chau F, Abel L: Amodiaquine-induced immune agranulocytosis. Br. J. Haematol. 71(1), 7-11 (1989).
9. Jewell H, Maggs JL, Harrison AC, O'Neill PM, Roscoe JE, Park BK: Role of hepatic metabolism in the bioactivation and detoxification of amodiaquine. Xenobiotica 25, 199-217 (1995).
10. Clarke JB, Maggs JL, Kitteringham NR, Park BK: Immunogenicity of amodiaquine in the rat. Int. Arch. Allergy Appl. Immunol. 91(4), 335-342 (1990).
11. Taylor WR, Terlouw DJ, Olliaro PL, White NJ, Brasseur P, ter Kuile FO: Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull. World health Organ. 84 (12), 956-964 (2006).
12. Hwang J, Bitarakwate E, Pai M, Reingold A, Rosenthal PJ, Dorsey G: Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review. Trop. Med. Int. Health 11(6), 789-799 (2006).
13. Orrell C, Taylor WR, Olliaro P: Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. Trans. R Soc. Trop. Med. Hyg. 95(5), 517-518 (2001).
14. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM: Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 300(2), 399-407 (2002).
15. Churchill FC, Patchen LC, Campbell CC, Schwartz IK, Nguyen-Dinh P, Dickinson CM: Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. Life Sci. 36(1), 53-62 (1985).
16. Furukawa M, Nishimura M, Ogino D et al.: Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci. 95(6), 520-529 (2004).
17. Tingle MD, Jewell H, Maggs JL, O'Neill PM, Park BK: The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro. chemical mechanisms and the effects of fluorine substitution. Biochem. Pharmacol. 50, 1113-1119 (1995).
18. Naisbitt DJ, Roscoe JE, Williams D, O'Neill PM, Pirmohamed M, Park BK: Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. J. Pharmacol. Exp. Ther. 280(2), 884-893 (1997).
19. Taylor WR, White NJ: Antimalarial drug toxicity: a review. Drug Saf. 27(1), 25-61 (2004).
20. Giao PT, de Vries PJ: Pharmacokinetic interactions of antimalarial agents. Clin. Pharmacakinet. 40(5), 343-373 (2001).
21. Hietala SF, Bhattarai A, Msellem M et al.: Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J. Pharmacokinet. Pharmacodyn. 34(5), 669-686 (2007).
22. Mariga ST, Gil JP, Sisowath C, Wernsdorfer WH, Björkman A: Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro. Antimicrob. Agents Cbemother. 48 (11), 4089-4096 (2004).
23. Winstanley P, Edwards G, Orme M, Breckenridge A: The disposition of amodiaquine in man after oral administration. Br. J. Clin. Pharmacol. 23(1), 1-7 (1987).
24. White NJ, Looareesuwan S, Edwards G et al.: Pharmacokinetics of intravenous amodiaquine. Br. J Clin. Pharmacol. 23(2), 127-135 (1987).
25. Hombhanje FW, Hwaihwanje I, Tsukahara T et al.: The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br. J. Clin. Pharmacol. 59(3), 298-301 (2005).
26. Gil J, Gil Berglund E: CYP2C8 and antimalaria drug efficacy. Pharmacagenomics 8(2), 187-198 (2007).
27. Cavaco I, Stromberg-Norklit J, Kaneko A et al.: CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur. J. Clin. Pharmacol. 61(1), 15-18 (2005).
28. Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL: Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin. Pharmacol. Ther. 82(2), 197-203 (2007).
29. Orrell C, Little F, Smith P et al.: Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur. J. Clin. Pharmacol. 64(7), 683-690 (2008).
30. Dai D, Zeldin DC, Blaisdell JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 11(7), 597-607 (2001).
31. Röwer S, Bienzle U, Weise A et al.: High prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop. Med. Int. Health. 10(12), 1271-1273 (2005).
32. Cavaco I, Piedade R, Gil JP, Ribeiro V: CYP2C8 polymorphism among the Portuguese. Clin. Chem. Lab. Med. 44(2), 168-170 (2006).
33. Singh R, Ting JG, Pan Y, Teh LK, Ismail R, Ong CE: Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab. Pharmacokinet. 23(3), 165-174 (2008).
34. White NJ: Antimalarial drug resistance. J. Clin. Invest. 113(8), 1084-1092 (2004).
35. Mårtensson A, Strömberg J, Sisowath C et al.: Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin. Infect. Dis. 41(8), 1079-1086 (2005).
36. Holmgren G, Hamrin J, Svärd J, Märtensson A, Gil JP, Björkman A: Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus arternisinin combination therapy in East Africa. Infect. Genet. Evol. 7(5), 562-569 (2007).
37. Barnes KI, Watkins WM, White NJ. Antimalarial dosing regimens and drug resistance. Trends Parasitol. 24(3), 127-134 (2008).
38. Hailing J, Petersen MS, Damkier P et al.: Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population, Eur J. Clin. Pharmacol. 61(7), 491-497 (2005).
39. Hruska MW, Frye RF, Langaee TY: Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin. Chem. 50(12), 2392-2395 (2004).
40. German P, Greenhouse B, Coates C et al.: Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin. Infect. Dis. 44 (6), 889-891 (2007).
41. Muthiah YD, Lee WL, Teh LK, Ong CE, Ismail R: Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians. J. Clin. Pharm. Ther. 30(5), 487-490 (2005).
42. Rynes RI: Antimalarial drugs in the treatment of rheumatological diseases. Br. J. Rheumatol. 36(7), 799-805 (1997).
43. Efferth T: Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 7(4), 407-421 (2006).
44. Mount DL, Patchen LC, Nguyen-Dinh P, Barber AM, Schwartz IK, Churchill FC: Sensitive analysis of blood for amodiaquine and three metabolites by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 383(2), 375-386 (1986).
45. Harrison AC, Kitteringham NR, Clarke JB, Park BK: The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem. Pharmacol. 43(7), 1421-1430 (1992).